La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Shandong Xinhua Pharmaceutical Bilan de santé
Santé financière contrôle des critères 6/6
Shandong Xinhua Pharmaceutical has a total shareholder equity of CN¥5.0B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 26.3%. Its total assets and total liabilities are CN¥8.5B and CN¥3.5B respectively. Shandong Xinhua Pharmaceutical's EBIT is CN¥482.9M making its interest coverage ratio 27.6. It has cash and short-term investments of CN¥922.1M.
Informations clés
26.3%
Ratio d'endettement
CN¥1.31b
Dette
| Ratio de couverture des intérêts | 27.6x |
| Argent liquide | CN¥922.05m |
| Fonds propres | CN¥4.99b |
| Total du passif | CN¥3.48b |
| Total des actifs | CN¥8.47b |
Mises à jour récentes de la santé financière
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Analyse de la situation financière
Passif à court terme: 719's short term assets (CN¥3.5B) exceed its short term liabilities (CN¥2.4B).
Passif à long terme: 719's short term assets (CN¥3.5B) exceed its long term liabilities (CN¥1.0B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 719's net debt to equity ratio (7.9%) is considered satisfactory.
Réduire la dette: 719's debt to equity ratio has reduced from 46% to 26.3% over the past 5 years.
Couverture de la dette: 719's debt is well covered by operating cash flow (37.1%).
Couverture des intérêts: 719's interest payments on its debt are well covered by EBIT (27.6x coverage).